Contract drugmaker Catalent shows signs of recovery in Q1 revenue beat

Catalent delays quarterly filing with SEC on $700 million impairment charge

Catalent revenue falls, delays annual report

Exclusive-Catalent nears settlement with Elliott for board seats -sources

Catalent, facing pressure from Elliott, had other activists in stock

Activist investor Elliott takes big stake in drugmaker Catalent - WSJ

Catalent reports bigger-than-expected loss on production challenges